Daiichi Sankyo commenced a Phase III trial of laninamivir, its inhaled drug candidate for H1N1 and bird flu infections. Daiichi plans to submit the drug for approval by March and launch it a year later.
Published in Brief:
|Chief Operating Officer||
Presence Health Partners
|Des Plaines, IL|
|Sr. Business Systems Analyst||
|Sr. Reimbursement Analyst||
Olympus America Inc.
|Leadership Recruiting Manager||
|Strategic Partner Relationship Executive||
Geisinger Health System